Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#746 Aspirin Delays the Development/Progression of Neuroendocrine Pancreatic Neoplasms and Prolongs Survival in a Transgenic Mouse Model of Islet Cell Tumors

Introduction: So far, there are no chemopreventive strategies for neuroendocrine pancreatic neoplasms.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Fendrich V

Authors: Fendrich V, Manoharan J, Lopez C, Waldmann J, Bartsch D,

Keywords: neuroendocrine pancreatic tumors, aspirin, chemoprevention,

#699 Ethanol Ablation in an 81-Year-Old Patient with Pancreatic Neuroendocrine Tumor (Islet Cell Tumor) and Severe Hypoglycemia – A Case Study.

Introduction: The key clinical problem in patients with islet cell tumors are persistent hypoglycemia episodes, which are particularly dangerous in the elderly since neuroglycopenia may be the cause of stroke.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Andrysiak-Mamos E, Starzyńska T, Białek A, Sowińska-Przepiera E, Kazmierczyk-Puchalska A,

Keywords: ethanol ablation, neuroendocrine tumor, islet cell tumor,

#524 Sunitinib in a MEN-1 Patient with Small Cell Neuroendocrine Tumor of the Thymus

Introduction: MEN-1 is an autosomal dominant disease caused by mutation of the oncosuppressor gene menin. MEN-1 is typically associated with hyperparathyroidism, islet cell tumors and pituitary adenomas, but it can also be associated with other neoplasms, such as thymic carcinoids.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Palmieri G, Buonerba C, Formisano L, Damiano V, Nappi L,

Keywords: MEN-1, Sunitinib, thymic caricnoids,

#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study

Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Papaxoinis G

Authors: Vaslamatzis M, Papaxoinis G, Tsiga A, Mantzaris G, Exarchos D,

Keywords: gastroenteropancreatic, neuroendocrine, tumors, pathology, characteristics, treatment,

#61 Multiple tumors in patients with pancreatic neuroendocrine tumours: morphological and immunohistochemical characteristics

Introduction: Pancreatic islet cell tumors occur in 80% of patients with MEN 1. Tumors are often multicentric. They often produce multiple peptides and biogenic amines.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Gurevich L, Egorov A, Askenderova E, Kubyshkin V, Kochatkov A,

Keywords: pancreatic islet cell tumor, pancreatic neuroendocrine tumor, MEN 1 syndrome, neuroendocrine marker, hormone,